Usha Panchapakesan

2.1k total citations
32 papers, 1.8k citations indexed

About

Usha Panchapakesan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Nephrology. According to data from OpenAlex, Usha Panchapakesan has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Molecular Biology and 8 papers in Nephrology. Recurrent topics in Usha Panchapakesan's work include Diabetes Treatment and Management (16 papers), Chronic Kidney Disease and Diabetes (8 papers) and Advanced Glycation End Products research (8 papers). Usha Panchapakesan is often cited by papers focused on Diabetes Treatment and Management (16 papers), Chronic Kidney Disease and Diabetes (8 papers) and Advanced Glycation End Products research (8 papers). Usha Panchapakesan collaborates with scholars based in Australia, Germany and United States. Usha Panchapakesan's co-authors include Carol A. Pollock, Steven J. Chadban, Harshini Mudaliar, Muralikrishna Gangadharan Komala, Jin Ma, Amanda Mather, Huiling Wu, Xinming Chen, Simon Gross and Peng Wang and has published in prestigious journals such as PLoS ONE, Scientific Reports and The FASEB Journal.

In The Last Decade

Usha Panchapakesan

32 papers receiving 1.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Usha Panchapakesan 681 593 585 379 321 32 1.8k
Daisuke Ogawa 816 1.2× 793 1.3× 605 1.0× 437 1.2× 259 0.8× 51 2.2k
Hitomi Usui 369 0.5× 444 0.7× 659 1.1× 249 0.7× 293 0.9× 14 1.6k
Elyce Ozols 256 0.4× 534 0.9× 744 1.3× 208 0.5× 392 1.2× 23 1.7k
Daiji Kawanami 599 0.9× 1.2k 2.0× 465 0.8× 340 0.9× 165 0.5× 81 2.7k
Bieke F. Schrijvers 306 0.4× 499 0.8× 651 1.1× 178 0.5× 308 1.0× 18 1.5k
Maria Lajer 466 0.7× 462 0.8× 431 0.7× 253 0.7× 138 0.4× 53 1.7k
Keiichiro Matoba 337 0.5× 480 0.8× 385 0.7× 166 0.4× 154 0.5× 41 1.2k
Tamotsu Yokota 315 0.5× 589 1.0× 338 0.6× 184 0.5× 149 0.5× 37 1.4k
Cristina Zanchi 262 0.4× 612 1.0× 1.0k 1.8× 306 0.8× 85 0.3× 30 2.1k
Torsten Kirsch 210 0.3× 759 1.3× 450 0.8× 234 0.6× 90 0.3× 41 1.9k

Countries citing papers authored by Usha Panchapakesan

Since Specialization
Citations

This map shows the geographic impact of Usha Panchapakesan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Usha Panchapakesan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Usha Panchapakesan more than expected).

Fields of papers citing papers by Usha Panchapakesan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Usha Panchapakesan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Usha Panchapakesan. The network helps show where Usha Panchapakesan may publish in the future.

Co-authorship network of co-authors of Usha Panchapakesan

This figure shows the co-authorship network connecting the top 25 collaborators of Usha Panchapakesan. A scholar is included among the top collaborators of Usha Panchapakesan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Usha Panchapakesan. Usha Panchapakesan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Panchapakesan, Usha & Carol A. Pollock. (2020). Organ protection beyond glycaemic control with SGLT2 inhibitors. Nature Reviews Nephrology. 17(4). 223–224. 3 indexed citations
2.
Panchapakesan, Usha & Carol A. Pollock. (2020). The primary cilia in diabetic kidney disease: A tubulocentric view?. The International Journal of Biochemistry & Cell Biology. 122. 105718–105718. 6 indexed citations
3.
Panchapakesan, Usha & Carol A. Pollock. (2018). Drug repurposing in kidney disease. Kidney International. 94(1). 40–48. 45 indexed citations
4.
Panchapakesan, Usha & Carol A. Pollock. (2017). The role of toll-like receptors in diabetic kidney disease. Current Opinion in Nephrology & Hypertension. 27(1). 30–34. 22 indexed citations
5.
Gallo, Linda A., Micheal Ward, Amelia K. Fotheringham, et al.. (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports. 6(1). 26428–26428. 126 indexed citations
6.
7.
Panchapakesan, Usha & Carol A. Pollock. (2015). The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease. Frontiers in Immunology. 6. 443–443. 35 indexed citations
8.
9.
Mudaliar, Harshini, Carol A. Pollock, Jin Ma, et al.. (2014). The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. PLoS ONE. 9(10). e108844–e108844. 92 indexed citations
10.
Ma, Jin, Steven J. Chadban, Cathy Zhao, et al.. (2014). TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PLoS ONE. 9(5). e97985–e97985. 132 indexed citations
11.
Panchapakesan, Usha, Simon Gross, Muralikrishna Gangadharan Komala, et al.. (2013). Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?. PLoS ONE. 8(2). e54442–e54442. 241 indexed citations
12.
Komala, Muralikrishna Gangadharan, Usha Panchapakesan, Carol A. Pollock, & Amanda Mather. (2012). Sodium glucose cotransporter 2 and the diabetic kidney. Current Opinion in Nephrology & Hypertension. 22(1). 113–119. 43 indexed citations
13.
Panchapakesan, Usha, Carol A. Pollock, & Sonia Saad. (2010). Renal epidermal growth factor receptor: Its role in sodium and water homeostasis in diabetic nephropathy. Clinical and Experimental Pharmacology and Physiology. 38(2). 84–88. 23 indexed citations
14.
Wu, Huiling, Jin Ma, Peng Wang, et al.. (2010). HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. Journal of the American Society of Nephrology. 21(11). 1878–1890. 294 indexed citations
15.
Panchapakesan, Usha, Carol A. Pollock, & Sonia Saad. (2009). Review article: Importance of the kidney proximal tubular cells in thiazolidinedione‐mediated sodium and water uptake. Nephrology. 14(3). 298–301. 19 indexed citations
16.
Panchapakesan, Usha, et al.. (2007). Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). International Journal of Nanomedicine. 2(1). 33–38. 10 indexed citations
17.
Panchapakesan, Usha, et al.. (2005). PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology-Renal Physiology. 289(5). F1153–F1158. 82 indexed citations
18.
Panchapakesan, Usha, Xinming Chen, & Carol A. Pollock. (2005). Drug Insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection. Nature Clinical Practice Nephrology. 1(1). 33–43. 39 indexed citations
19.
Panchapakesan, Usha, Carol A. Pollock, & Xinming Chen. (2004). The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells. American Journal of Physiology-Renal Physiology. 287(3). F528–F534. 68 indexed citations
20.
Panchapakesan, Usha, et al.. (2003). Recovery of pure red‐cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Internal Medicine Journal. 33(9-10). 468–471. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daisuke Ogawa Breakdown of academic impact, for papers by Hitomi Usui Breakdown of academic impact, for papers by Elyce Ozols Breakdown of academic impact, for papers by Daiji Kawanami Breakdown of academic impact, for papers by Bieke F. Schrijvers Breakdown of academic impact, for papers by Maria Lajer Breakdown of academic impact, for papers by Keiichiro Matoba Breakdown of academic impact, for papers by Tamotsu Yokota Breakdown of academic impact, for papers by Cristina Zanchi Breakdown of academic impact, for papers by Torsten Kirsch
Rankless by CCL
2026